ScholarIQanswers from OpenAlex

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib

PaperCitations, authors & open-access status

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is a paper indexed in ScholarIQ from OpenAlex.

How many citations does TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib have?

ScholarIQcitation count

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib has 69 citations in the OpenAlex counts ScholarIQ stores.

When was TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib published?

ScholarIQyear

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib has 2018 year in the ScholarIQ index.

What is the open-access status of TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?

ScholarIQoa status

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib has diamond oa status in the ScholarIQ index.

What is the DOI of TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?

ScholarIQdoi

The DOI for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is on the source record.

What is the PMID of TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?

ScholarIQpmid

The PMID for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is on the source record.

What is the OpenAlex record for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib?

ScholarIQopenalex

The OpenAlex for TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial